John J. Alam (United States of America)
EIP Pharma, Inc.
Medical
John Alam is President and CEO of EIP Pharma, and is on the board of directors for Alliance for Aging Research (Washington DC). Until May 2014, he was therapeutic area head for diseases of aging within Sanofi R&D. In that role he led on a global basis R&D activity at Sanofi directed at Alzheimer’s and Parkinson’s disease, as well as number of other age-related diseases. Previously, from 1997 until 2008 he held positions of increasingly responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and EVP, Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. And, from 1991 to 1997, while at Biogen, Inc, he led the clinical development of Avonex (interferon beta-1a). John received a S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Subsequently, he completed an internal medicine residency at Brigham and Women’s Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.

Moderator of 1 Session

 Conference Calendar
SYMPOSIUM

ADVANCES IN PD AND LBD DRUG DEVELOPMENT 2

Session Type
SYMPOSIUM
Date
Sun, 20.03.2022
Session Time
11:35 AM - 01:20 PM
Room
ONSITE: 114
Chair(s)

Presenter of 1 Presentation

 Conference Calendar

EFFECTS ON COGNITION AND FUNCTION ASSESSED BY CDR-SB OF THE ORAL P38Α KINASE INHIBITOR NEFLAMAPIMOD IN PATIENTS WITH MILD-TO-MODERATE DEMENTIA WITH LEWY BODIES (DLB)

Session Name
1980 - ADVANCES IN PD AND LBD DRUG DEVELOPMENT 2 (ID 102)
Session Type
SYMPOSIUM
Date
Sun, 20.03.2022
Session Time
11:35 AM - 01:20 PM
Room
ONSITE: 114
Lecture Time
11:35 AM - 11:50 AM
Presenter

Abstract

Aims

Compared to episodic-memory-focused cognitive tests such as the ADAS-COG, the Clinical Dementia Rating sum-of-boxes (CDR-SB), in addition to also evaluating function, is potentially better suited to evaluate the cognitive deficits seen in DLB. However, there is limited information on its utility in that context. The aim of this abstract is to report CDR-SB results in a phase 2 placebo (PBO)-controlled study of neflamapimod (NFMD) in DLB. The initial results of that study, presented previously at another scientific conference, demonstrated that 40mg TID neflamapimod significantly improves, relative to placebo, both cognition (evaluated by Neuropsychological Test Battery designed to assess attention and executive function) and motor function (evaluated by Timed Up and Go Test).

Methods

Mild-to-moderate DLB, including abnormal DaT-scan, receiving cholinesterase-inhibitor therapy. Randomized to 40mg NFMD capsules or matching PBO capsules for 16 weeks; BID (<80kg participants) or TID (≥ 80 kg participants). Treatment effects evaluated by linear-mixed-effects-model for repeated measures, with baseline as a covariate.

Results

Baseline mean(N,SD) CDR-SB score: 5.1(42,2.9) in placebo and 4.9(41,2.1) in NFMD. In PBO, there was a significant increase (worsening; +0.67 points, 95%CI:0.13 to 1.21) in CDR-SB from baseline to week 16. There were significant differences favoring neflamapimod treatment in comparisons of all NFMD vs. all PBO (p=0.023, difference=-0.45, 95%CI:-0.83 to -0.06), 40mg TID vs. all PBO (p=0.007, difference= 0.56, 95%CI:-0.96 to -0.16), and NFMD 40mg TID vs. PBO TID (p=0.005, difference=-0.63, 95%CI:-1.06 to -0.21).

Conclusions

CDR-SB proved useful to demonstrate beneficial effects, relative to placebo, of neflamapimod treatment on cognition and function in patients with mild-to-moderate DLB.

Hide